Department of Regulatory Affairs, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, 500037, India.
Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, 500037, India.
Pharm Pat Anal. 2023 Nov;12(6):261-273. doi: 10.4155/ppa-2023-0024. Epub 2024 Jan 12.
Pancreatic adenocarcinoma, a devastating disease, has the worst cancer prognosis in humans. It often develops resistance to common chemotherapy medications, such as gemcitabine, taxol and 5-fluorouracil. The dense stroma limits therapeutic efficacy in treating this disease. Low or limited drug loading capacity is another problem with current chemotherapeutic agents. There is a need to develop novel approaches to overcome these issues. Hence, an innovative approach has been proposed to co-deliver both hydrophilic (Gemcitabine) and hydrophobic (Paclitaxel) drugs in a single carrier using lipid bilayer-mesoporous silica nanoparticles (LB-MSNP). MSNPs offer effective drug delivery due to their superior bioavailability and physicochemical properties. Further, in order to achieve clinical translation and regulatory approval, toxicity and biodegradability of MSNPs must be resolved.
胰腺导管腺癌是一种具有破坏性的疾病，其预后是所有人类癌症中最差的。它通常对常见的化疗药物（如吉西他滨、紫杉醇和 5-氟尿嘧啶）产生耐药性。密集的基质限制了治疗这种疾病的疗效。目前的化疗药物还存在载药量低或有限的问题。因此，需要开发新的方法来克服这些问题。因此，提出了一种创新的方法，使用脂质双层-介孔硅纳米粒子（LB-MSNP）将亲水性（吉西他滨）和疏水性（紫杉醇）药物共同递送到单一载体中。MSNPs 具有优越的生物利用度和物理化学性质，因此能够有效地递药。此外，为了实现临床转化和监管批准，必须解决 MSNPs 的毒性和生物降解性问题。
